QED Pharmaceutical Services Picks SAS Clinical Data Integration to Help Clients Implement CDISC Standards
QED Pharmaceutical Services has licensed SAS® Clinical Data Integration to enable its drug development clients to more easily form partnerships with key biopharmaceutical companies. SAS offers a comprehensive portfolio of life sciences software solutions for pharmaceutical, biotechnology and medical device companies.
“The availability of SAS Clinical Data Integration has made it possible for QED to efficiently implement complex data standards such as the CDISC standards,” said Dr. Ramana Kuchibhatla, QED founder. “This allows us to help our clients - predominantly small and sometimes virtual biopharmaceutical companies - achieve important milestones despite their size. Compliance with the latest CDISC standards makes growing drug developers like our clients very attractive partners to large pharma companies that are looking to in-license successful drug development programs. ”
QED also uses other SAS products including SAS® Enterprise Business Intelligence. With the knowledge base created by these systems, QED can offer cost-effective services for its clients. “It’s as if we have designed an efficient mechanical engine, and now, with little modification for each clinical trial, we can crank out CDISC-compliant data and get our clients’ datasets output in regulatory submission-ready formats,” said Kuchibhatla.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
